Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | CNR1 | P21554 | 1/20 | 0.56 |
| ▸ | CNR2 | P34972 | 1/20 | 0.56 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.45 |
| ▸ | LPAR3 | Q9UBY5 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3244647 | 1.00 | ALDH1A1 (0.56) | ALDH1A1CNR1CNR2LPAR1LPAR3 | |
| SCHEMBL12957711 | 1.00 | ALDH1A1 (0.56) | ALDH1A1CNR1CNR2LPAR1LPAR3 | |
| SCHEMBL12841669 | 1.00 | ALDH1A1 (0.56) | ALDH1A1CNR1CNR2LPAR1LPAR3 | |
| SCHEMBL11913767 | 0.97 | ALDH1A1 (0.53) | ALDH1A1CNR1CNR2LPAR1LPAR3 | |
| SCHEMBL12769198 | 0.97 | ALDH1A1 (0.53) | ALDH1A1CNR1CNR2LPAR1LPAR3 | |
| SCHEMBL12960143 | 0.97 | ALDH1A1 (0.53) | ALDH1A1CNR1CNR2LPAR1LPAR3 | |
| SCHEMBL12957786 | 0.97 | ALDH1A1 (0.53) | ALDH1A1CNR1CNR2LPAR1LPAR3 | |
| SCHEMBL11913757 | 0.97 | ALDH1A1 (0.53) | ALDH1A1CNR1CNR2LPAR1LPAR3 | |
| SCHEMBL24493616 | 0.96 | ALDH1A1 (0.51) | ALDH1A1CNR1CNR2LPAR1LPAR3 | |
| Hydrochloric Acid SCHEMBL1263206 | 0.95 | ALDH1A1 (0.48) | ALDH1A1CNR1CNR2LPAR1LPAR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 174 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100099738-A1 | POLYETHYLENE GLYCOL LIPID CONJUGATES AND USES THEREOF | ABBOTT LABORATORIES (US) | 2010-04-22 | — | — | US | claimed |
| US-20100076055-A1 | Cationic Lipids and Uses Thereof | ABBOTT LABORATORIES (US) | 2010-03-25 | — | — | US | claimed |
| WO-2010030739-A1 | POLYETHYLENE GLYCOL LIPID CONJUGATES AND USES THEREOF | ABBOTT LABORATORIES (US) | 2010-03-18 | — | — | WO | claimed |
| US-20100063135-A1 | POLYETHYLENE GLYCOL LIPID CONJUGATES AND USES THEREOF | ABBOTT LABORATORIES (US) | 2010-03-11 | — | — | US | claimed |
| US-20100055169-A1 | CATIONIC LIPIDS AND USES THEREOF | ABBOTT LABORATORIES (US) | 2010-03-04 | — | — | US | claimed |
| US-12606823-B2 | Modified CPF1 guide RNA | Breeze Bio, Inc. | 2026-04-21 | — | — | US | disclosed |
| US-12016929-B2 | Lipid formulations for delivery of therapeutic agents | ARBUTUS BIOPHARMA CORPORATION (CA) | 2024-06-25 | — | — | US | disclosed |
| US-12016929-B2 | Lipid formulations for delivery of therapeutic agents | ARBUTUS BIOPHARMA CORPORATION (CA) | 2024-06-25 | — | — | US | disclosed |
| US-20240182895-A1 | NON-LIPOSOMAL SYSTEMS FOR NUCLEIC ACID DELIVERY | ARBUTUS BIOPHARMA CORPORATION (CA) | 2024-06-06 | — | — | US | disclosed |
| US-20240148875-A1 | NOVEL LIPID FORMULATIONS FOR DELIVERY OF THERAPEUTIC AGENTS | ARBUTUS BIOPHARMA CORPORATION (CA) | 2024-05-09 | — | — | US | disclosed |
| WO-2024073678-A2 | PHOSPHOLIPIDS CONTAINING A HETEROCYCLE RING HAVING A TERTIARY AMINE OR AMIDE | OMEGA THERAPEUTICS, INC. (US) | 2024-04-04 | — | — | WO | disclosed |
| US-20240100166-A1 | NOVEL LIPID FORMULATIONS FOR DELIVERY OF THERAPEUTIC AGENTS | ARBUTUS BIOPHARMA CORPORATION (CA) | 2024-03-28 | — | — | US | disclosed |
| WO-2011000107-A1 | NOVEL LIPID FORMULATIONS FOR DELIVERY OF THERAPEUTIC AGENTS TO SOLID TUMORS | PROTIVA BIOTHERAPEUTICS, INC. (CA) | 2011-01-06 | — | — | WO | disclosed |
| WO-2011000106-A1 | IMPROVED CATIONIC LIPIDS AND METHODS FOR THE DELIVERY OF THERAPEUTIC AGENTS | PROTIVA BIOTHERAPEUTICS, INC. (CA) | 2011-01-06 | — | — | WO | disclosed |
| WO-2011000108-A1 | COMPOSITIONS AND METHODS FOR SILENCING APOLIPOPROTEIN B | PROTIVA BIOTHERAPEUTICS, INC. (CA) | 2011-01-06 | — | — | WO | disclosed |
| US-20100099738-A1 | POLYETHYLENE GLYCOL LIPID CONJUGATES AND USES THEREOF | ABBOTT LABORATORIES (US) | 2010-04-22 | — | — | US | disclosed |
| US-20100076055-A1 | Cationic Lipids and Uses Thereof | ABBOTT LABORATORIES (US) | 2010-03-25 | — | — | US | disclosed |
| WO-2010030739-A1 | POLYETHYLENE GLYCOL LIPID CONJUGATES AND USES THEREOF | ABBOTT LABORATORIES (US) | 2010-03-18 | — | — | WO | disclosed |
| US-20100063135-A1 | POLYETHYLENE GLYCOL LIPID CONJUGATES AND USES THEREOF | ABBOTT LABORATORIES (US) | 2010-03-11 | — | — | US | disclosed |
| US-20100055169-A1 | CATIONIC LIPIDS AND USES THEREOF | ABBOTT LABORATORIES (US) | 2010-03-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100099738-A1 | POLYETHYLENE GLYCOL LIPID CONJUGATES AND USES THEREOF | LIPA, LIPG, LIPC | ALDH1A1 1734/4885CNR1 3492/4885CNR2 3231/4885 |
| US-20100063135-A1 | POLYETHYLENE GLYCOL LIPID CONJUGATES AND USES THEREOF | LIPA, LIPG, LIPC | ALDH1A1 1734/4885CNR1 3492/4885CNR2 3231/4885 |
| US-20240100166-A1 | NOVEL LIPID FORMULATIONS FOR DELIVERY OF THERAPEUTIC AGENTS | PNLIP, NPC1L1, CETP | ALDH1A1 2161/4885CNR1 3653/4885CNR2 3995/4885 |
| US-20240182895-A1 | NON-LIPOSOMAL SYSTEMS FOR NUCLEIC ACID DELIVERY | SNRPE, NPC1L1, LIPA | ALDH1A1 3573/4885CNR1 4202/4885CNR2 4528/4885 |
| US-20100076055-A1 | Cationic Lipids and Uses Thereof | LIPA, SGMS2, SGMS1 | ALDH1A1 4724/4885CNR1 3144/4885CNR2 2239/4885 |
| US-20240148875-A1 | NOVEL LIPID FORMULATIONS FOR DELIVERY OF THERAPEUTIC AGENTS | PNLIP, NPC1L1, CETP | ALDH1A1 2161/4885CNR1 3653/4885CNR2 3995/4885 |
| US-12606823-B2 | Modified CPF1 guide RNA | CPSF1, CPSF6, UPF1 | ALDH1A1 4235/4885CNR1 3590/4885CNR2 4023/4885 |
| US-20100055169-A1 | CATIONIC LIPIDS AND USES THEREOF | LIPA, SGMS2, SGMS1 | ALDH1A1 4724/4885CNR1 3144/4885CNR2 2239/4885 |
| US-12016929-B2 | Lipid formulations for delivery of therapeutic agents | CETP, PNLIP, NPC1L1 | ALDH1A1 1878/4885CNR1 3702/4885CNR2 4058/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.